Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue
Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue
MENLO PARK, Calif., Jan. 11, 2021 Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2020 are not yet available.
Financial and Operational Highlights
Preliminary fourth quarter revenue is expected to be approximately $27 million, representing an estimated increase of approximately 41% sequentially compared with $19.1 million for the third quarter of 2020.